Gilead Kite vice president leaves, Bayer CEO term extended...

Recently, a number of multinational pharmaceutical companies announced the company's executive personnel changes.
the flow of biomedical talents means that the economic vitality of the industry continues to develop.
the new and old rotation of professionals, but also one of the signs of industrial change and opportunity rush.
: Kite's current vice president of cell therapy research left the company on September 14, according to Endpoint News.
Peter Emage's role will now be temporarily taken over by Ken Takeshita, Senior Vice President and Global Head of Clinical Development at Kite, and the company will continue to seek a new successor, according to people familiar with the matter.
, an immunologist, has been developing drugs that regulate the human immune response for the past 20 years.
he promotes the development of cell therapy by using viral and non-viral delivery systems, embedded antigens and TCR oversuperitive T-cell patterns, and monoclonal antibodies for checkpoint blocking and immuno-oncology.
Bayer's CEO term was extended until 10 September 2024, and according to a statement on Bayer's official website, Bayer's Supervisory Board unanimously decided to extend the contract of Werner Baumann, Chairman and CEO of the Management Committee, until 30 April 2024, with a original deadline of 30 April 2021.
in 2019, Werner Bowman faced a vote of no confidence from Bayer shareholders over a $63 billion lawsuit to buy seed maker Monsanto and Roundup.
55.5 per cent of shareholders believe he and his management did not carefully assess the legal risks of the acquisition during the transaction.
Bayer's Roundup lawsuit was shelved after a new outbreak of pneumonia this year.
also benefited from a strong stockpile of prescription drugs, Bayer achieved sales of EUR 12.845 billion in the first quarter of 2020, an adjusted 6% year-on-year increase, and a net profit of EUR 1,489 million, up 20% year-on-year.
report card has given Werner Bowman renewed investors' trust and support.
BMS Head of Oncology Research and Development joined Blueprint on September 1, and Fouad Namouni, former head of BMS Oncology Research and Development, joined Blueprint Pharmaceuticals as President of Research and Development, overseeing the entire drug development cycle from discovery to regulatory approval.
it is understood that Fouad Namouni, a 20-year veteran of BMS, has been involved in and led the development team for the immuno-oncology star drugs Opdivo and Yervoy.
will earn $550,000 a year when he joins the new company and will receive more than $2 million in stock dividends over the next four years, according to the Securities and Exchange Commission.
Pharmaceuticals is an innovative biopharmaceutical company focused on cancer personality therapies.
its core product is the RET kinase inhibitor Gawreto (pralsetinib, Platini), which was approved by the FDA on September 4, 2020 for the treatment of RET fusion-positive metastasis non-small cell lung cancer (NSCLC).
was accepted by CDE on September 7 and included in the priority review, and is expected to become the first RET targeted therapeutic drug in China.
it is worth mentioning that Keystone Pharmaceuticals has exclusive clinical development and commercial rights to Platini monodone or combined therapy in Greater China, including Chinese mainland, Hong Kong, Macau and Taiwan.
owns global exclusive licenses for the drug in Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan) and markets outside the United States, as well as the right to jointly develop and commercialize Platinib in the United States with Blueprint.
in addition to Fouad Namouni, three veterans from multinational pharmaceutical companies have gone to start-up biotech companies, including: 1, Dr Lisa Olson, who has worked for Abbvie for 15 years, will join Magenta Therapeutics as Chief Scientific Officer (CSO).
Magenta is a biotechnology company dedicated to the development of revolutionary bone marrow transplants for autoimmune diseases, blood cancers and genetic diseases.
has pioneered an integrated approach to pre-transplant preparation, stem cell collection, stem cell amplification, and post-transplant complications to expand the healing power of bone marrow transplantation to more patients by making the process more effective, safe, and easy.
Edmondson, a former Director and Director of AstraZenechem Boston Oncology Chemistry, joined Nimbus Therapeutics as Senior Vice President and Head of Chemistry.
Nimbus is a biotechnology company dedicated to the use of computer technology expertise to promote drug discovery and development.
company's HPK1 inhibitors are expected to be innovative treatments for cancer, or in combination with existing cancer immunotherapy, to improve the effectiveness of cancer treatment.
3, charles Hugh-Jones, former chief marketing officer (CMO) of Allergan, joined Volastra Therapeutics, a U.S. metastasis cancer therapy developer, as CEO.
Volastra Therapeutics is a company dedicated to developing new therapies for metastatic cancer patients through unique insights into unstable chromosomes, focusing on the development of metastatic cancer therapies through targeted pathways related to unstable chromosomes.
February, Volastra completed a $12 million seed round, led by Polaries Partners, DROIA Oncology Ventures, Arch Venture Partners and Global Health Sciences Fund.
original title: The departure of Vice President Gilead Kite, the extension of bayer's CEO term, the addition of the head of BMS oncology research and development to Blueprint...